Literature DB >> 7850978

Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina.

A M Zeiher1, H Goebel, V Schächinger, C Ihling.   

Abstract

BACKGROUND: The pathomorphological substrate of complicated coronary atherosclerotic lesions underlying unstable angina is characterized by a localized chronic inflammatory process. Functionally, coronary lesions associated with unstable angina demonstrate an enhanced vasoreactivity. Endothelin-1 is a potent vasoconstrictor peptide produced not only by endothelial cells but also by macrophages and polymorphonuclear leukocytes, the cell types characteristic of inflammation. METHODS AND
RESULTS: By use of immunohistochemical techniques, we examined the presence of endothelin-1 in coronary atherosclerotic plaque tissue obtained by directional coronary atherectomy of primary lesions from 50 consecutive patients. The tissue specimens of 43 of 50 patients (86%) demonstrated endothelin-1-like immunoreactivity. Endothelin-1-like immunoreactivity preferentially localized to macrophage-rich areas, to hypercellular regions rich in microvessels, and to plaque areas with evidence of prior hemorrhage. Double-immunolabeling revealed that both macrophages (HAM56 positive) and intimal smooth muscle cells (alpha-actin positive) demonstrated cytoplasmic immunostaining for endothelin-1. Semiquantitative analysis of endothelin-1-like immunostaining revealed significantly (P < .005) higher staining grades in active (1.86 +/- 0.15, n = 40) compared with nonactive lesions (0.78 +/- 0.35, n = 10): endothelin-1 staining grades were significantly (P < .001) lower in patients with stable angina (0.69 +/- 0.19, n = 13) than in patients with crescendo angina (1.82 +/- 0.30, n = 11), with angina at rest (2.08 +/- 0.21, n = 12), or with angina after myocardial infarction (2.0 +/- 0.26, n = 14).
CONCLUSIONS: Endothelin-1 immunostaining of atherosclerotic tissue localizes predominantly with plaque components indicative of chronic inflammatory processes. The increased tissue endothelin-1-like immunoreactivity in active coronary atherosclerotic lesions may provide a clue to the mechanisms of increased vasoreactivity of the culprit lesion in acute ischemic syndromes, which is the clinical substrate of the active coronary atherosclerotic plaque.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850978     DOI: 10.1161/01.cir.91.4.941

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

1.  C reactive protein and microvascular function.

Authors:  F Tomai
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

Review 2.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

3.  Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression.

Authors:  Neetu Sud; Stephen M Black
Journal:  DNA Cell Biol       Date:  2009-11       Impact factor: 3.311

Review 4.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Endothelin-1 production by the canine macrophage cell line DH82: enhanced production in response to microbial challenge.

Authors:  Jeffrey N Divino; Kashmira S Chawla; Christina M da Silva; Ashley M Bjorge; Andrew Brittingham
Journal:  Vet Immunol Immunopathol       Date:  2010-02-13       Impact factor: 2.046

Review 6.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Severe depressive symptoms are associated with elevated endothelin-1 in younger patients with acute coronary syndrome.

Authors:  Luba Yammine; Lorraine Frazier; Nikhil S Padhye; Matthew M Burg; Janet C Meininger
Journal:  J Psychosom Res       Date:  2014-08-02       Impact factor: 3.006

Review 8.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

9.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 10.  Reactive oxygen species-activated nanomaterials as theranostic agents.

Authors:  Kye S Kim; Dongwon Lee; Chul Gyu Song; Peter M Kang
Journal:  Nanomedicine (Lond)       Date:  2015-09-02       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.